Ostarine

Ostarine, also known by its research code MK-2866 or Enobosarm, is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar effects to androgenic drugs but with reduced androgenic side effects. Ostarine was originally developed for conditions such as muscle wasting and osteoporosis. It is considered an investigational compound and is not approved by the U.S. Food and Drug Administration (FDA) for human consumption or therapeutic use. Despite its unapproved status, Ostarine has gained attention in some communities for its potential to increase muscle mass and improve physical performance. Unlike traditional anabolic steroids, which can affect many tissues throughout the body, SARMs like Ostarine are designed to selectively target androgen receptors in specific tissues, primarily muscle and bone. This selectivity is intended to provide the beneficial anabolic effects on these tissues while minimizing unwanted androgenic effects on other tissues, such as the prostate or hair follicles. Research into Ostarine's properties is ongoing, exploring its potential applications in clinical settings and understanding its full profile of effects and safety.